Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trialSherene Loi, Christos Sotiriou, Roberto Salgado et al.|Annals of Oncology|2014Cited by 1.3k